Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Fluorouracil- (FU-) based adjuvant therapy is an established therapy for patients with resected high-risk colon cancer. This tool provides the results from a pooled analysis of 3302 patients from seven randomised trials and compares the magnitude of adjuvant therapy benefit across specific subgroups.
This table presents computed estimates for age-specific 5-year overall survival (%) in patients with resected colon cancer with/without 5FU-based adjuvant chemotherapy. There is a section for Low grade and a section for High grade.
A pooled analysis of adjuvant chemotherapy trials for patients with resected colon cancer was performed to quantify the benefit of 5FU-based chemotherapy for predefined clinical and pathologic subgroups. The table below provides individualized estimates of baseline prognosis and adjuvant-therapy benefit based on T stage, nodal status and grade.
Using the end point of 5-year DFS, the model was evaluated for discriminating ability, calibration and over-fitting. The calibration of the model was assessed by comparing the predicted 5-year DFS rates for surgery alone and for surgery plus adjuvant therapy with the corresponding observed or Kaplan-Meier estimate probabilities.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
